Cipla gets US FDA go-ahead earlier than anticipated for first generic of Merck’s Proventil, setting the stage for increased competition in the albuterol segment, where demand is up amid the coronavirus pandemic.

Cipla is to moderate investments across its US generics R&D and specialty business, while its India business components – prescription, trade generic and consumer health – are being brought under a “single capital allocation framework.”

Cipla to moderate investments across US generics R&D and specialty business, while its India business components - prescription, trade generic and consumer health - are being brought under a “single capital allocation framework.”